In an extraordinary development, a second European scientific trial of pre-exposure prophylaxis (PrEP) has had its randomised phase closed early due to high effectiveness, just two weeks after the UK PROUD trial did exactly the same thing. The investigators of the IPERGAY trial, which has six sites in France and one in Canada, announced today a “Significant breakthrough in the fight against HIV and AIDS” because IPERGAY had successfully demonstrated the effectiveness of its PrEP regimen.
The ANRS IPERGAY trial demonstrates the effectiveness of a preventive treatment (antiretroviral treatment) against HIV/AIDS when taken at the time of sexual intercourse. All trial participants will now benefit from this prophylaxis. Read More